Pulmonary Artery Denervation (PADN) Treatment in Patients with Pulmonary Hypertension Due to Left Heart Disease: Initial Results of the PreVail-PH2 Early Feasibility Study

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Abbott Vascular; Edwards Lifesciences; Merck/Schering Plough; Gradient; Boston Scientific Corporation; Aria CV</li><li>Travel to meeting - Abiomed</li><li>Consultant Fee/Honoraria/Speaker's Bureau - Acorai; Adona; Endotronix, Inc.; Fauna Bio; morphic therapeutics; Medtronic; Imbria; Pulmovant; Restore medical; Tempus AI; United Therapeutics</li><li>Equity/Stock(s)/Options - Aria CV; Acorai</li><li>travel to meeting - CVRx</li></ul>